Pham Quang X sold $9K of CVKD
Pham Quang X (CEO and Chairman) sold 2,064 shares of Cadrenal Therapeutics, Inc. (CVKD) at $4.42 on 2026-06-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may influence short-term sentiment/positioning, but it does not introduce new operational or clinical information.
Market read
A same-day insider sale at a disclosed price can slightly pressure sentiment, though 10b5-1 typically limits interpretive value.
What to watch
Consider whether multiple insiders are selling around the same time; a single Form 4 often has limited standalone signal.
Background
This is an SEC insider transaction (Form 4) for Cadrenal Therapeutics, reported by the CEO/Chairman and 10% owner.
Ticker impact
Cadrenal Therapeutics CEO/Chairman Pham Quang X sold 2,064 shares in an open-market transaction disclosed via SEC Form 4.
Likely limited immediate impact; any effect is more sentiment/flow-driven than fundamental.
The filing provides a concrete sale price/size, but the presence of a Rule 10b5-1 plan reduces interpretability as new negative information.
Market effects
For small-cap biopharma, routine 10b5-1 insider sales can modestly affect sentiment but rarely reset fundamentals.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider sale disclosed on 2026-06-05.
- insiderPham Quang X
CEO and Chairman; sold 2,064 shares at $4.4200 under a 10b5-1 plan.
